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Developing countries have limited healthcare resources and use different strategies to diagnose breast cancer.
Most of the population depends on the public healthcare system, which affects the diagnosis of the tumor.
Thus, the indicators observed in developed countries cannot be directly compared with those observed in
developing countries because the healthcare infrastructures in developing countries are deficient. The aim of
this study was to evaluate breast cancer screening strategies and indicators in developing countries.
A systematic review and the Population, Intervention, Comparison, Outcomes, Timing, and Setting methodology
were performed to identify possible indicators of presentation at diagnosis and the methodologies used in
developing countries. We searched PubMed for the terms ‘‘Breast Cancer’’ or ‘‘Breast Cancer Screening’’ and
‘‘Developing Country’’ or ‘‘Developing Countries’’.
In all, 1,149 articles were identified. Of these articles, 45 full articles were selected, which allowed us to identify
indicators related to epidemiology, diagnostic intervention (diagnostic strategy, diagnostic infrastructure,
percentage of women undergoing mammography), quality of intervention (presentation of symptoms at
diagnosis, time to diagnosis, early stage disease), comparisons (trend curves, subpopulations at risk) and survival
among different countries.
The identification of these indicators will improve the reporting of methodologies used in developing countries
and will allow us to evaluate improvements in public health related to breast cancer.
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’ INTRODUCTION
Breast cancer is a global problem, and 1.7 million new
cases are diagnosed per year. Approximately 60% of deaths
due to breast cancer occur in developing countries (DCs) (1),
whereas in the United States (US), an estimated 249,260 new
cases of breast cancer are diagnosed each year, and mortality
due to this disease is decreasing (2). In contrast, breast cancer
in DCs represents one-half of all breast cancer cases and 62%
of the deaths (1). In Brazil, it is expected that the incidence of
breast cancer will be about one-fourth that of the US, but this
increased incidence is associated with an increase in breast
cancer-associated mortality (3).
Despite advances in medicine, breast cancer is diagnosed
in the advanced stages in countries with limited resources
because early detection, diagnosis, and treatment cannot
be efficiently promoted. To evaluate the complexity of the
healthcare system in relation to breast cancer, the ‘‘Breast
Health Global Initiative’’ (BHGI) (4) has sought to categorize
the organizational levels of countries in relation to breast
cancer. Specifically, at the basic level, breast self-examination
is encouraged, whereas diagnostic ultrasound and mammo-
graphy are available at a limited level. At the increased level,
patients have access to diagnostic mammography with oppor-
tunistic breast screening, and at the maximum level, the popu-
lation undergoes organized screening for breast cancer (4).
In the US, 70% of women undergo mammographies. This
percentage is higher in white women (72.1%), women with a
higher level of education (80.1%), women born in the USA
(71.6%), and women with health insurance (73.6%) (5). In coun-
tries with budgetary limits, the percentage of cancer diagnosis
in the presence of a palpable mass (6) and adherence strategies
based on self-breast examination are being discussed (7).
The prognosis for breast cancer is considered good. The
survival rate is on the order of 73% in developed countries
and 57% in DCs. In the US, the 5-year survival rate is
89.7% (8, 9). Although the incidence of breast cancer is
lower in DCs, the mortality/incidence ratio is higher (8). Due
to economic and logistical constraints, a limited organizedDOI: 10.6061/clinics/2017(04)09
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network is aimed at the early diagnosis of breast cancer
in DCs. Mammographic screening is not a reality, which
is reflected in the high number of patients diagnosed at an
advanced stage.
It is difficult to compare or evaluate the health systems of
DCs, and it is also difficult to evaluate their improvement.
Based on this condition, it is important to consider indicators
that indirectly reflect the status and evolution of public health
systems related to breast cancer screening and diagnosis. It is
a challenge to identify possible indicators associated with the
diagnosis of early breast cancer because these populations
lack real indirect indicators related to breast cancer screening
and indicators that can evaluate progressive improvements to
the healthcare system or that can compare healthcare systems
among DCs. The identification of these indicators and the
subsequent comparisons are the purpose of this study.
’ MATERIALS AND METHODS
This study consists of an integrative systematic review based
on a systematic search methodology to evaluate possible indi-
cators related to methods of breast cancer screening and
diagnosis in DCs. According to the Brazilian National Ethics
Committee resolution 466, systematic reviews do not need to
be evaluated by an Ethics Committee. Study methodologies
were not evaluated, but rather, publications that discussed this
subject were examined.
The PubMed database was searched using the keywords
‘‘Breast Cancer’’ or ‘‘Breast Cancer Screening’’ and ‘‘Develop-
ing Country’’ or ‘‘Developing Countries’’. This search returned
1,149 articles published between April 1974 to September 30th,
2015.
After reading the titles and abstracts, we identified 100
potential articles discussing breast cancer indicators and
screening characteristics. All 100 identified articles were read
in full by two researchers (GB and RACV). Eighteen articles
were excluded because they were review articles on screen-
ing strategies in DCs; 7 articles were excluded because they
exclusively addressed underdeveloped countries; 3 articles
were excluded because they were published in the 1990s and
were superseded by subsequent publications with different
data; 27 articles were excluded for various reasons. Thus,
the 45 articles that were reviewed included numerical data
regarding diagnostic methodology and tumor presentation
at diagnosis. We included observational studies, prevalence
studies and prevalence review articles. A summary of the
results is shown in Figure 1.
We attempted to use the systematic review elements
formatting structure, PICOTS (Population- Intervention-
Comparator- Outcome- Timing- Setting) (10, 11), associating
elements suggested by the BHGI for DCs (4), and quality
criteria to be used in mammographic screening (12). A
Microsoft Excels table was generated, which identified the
PMID, first author, main results and potential indicators
based on the PICOTS structure. We then attempted to group
studies according to subject matter, taking into account items
that reflected a possible health indicator, the methodology
used for breast cancer diagnosis, or items that reflected the
characteristics of breast cancer patients in DCs (Table 1).
The results observed for each item were then described to
better understand the characteristics of mammographic
screening and possible outcomes observed in DCs.
’ RESULTS
Based on PICOTS, where the scenario (Setting) is breast
cancer diagnosis in DCs, a lack of controlled studies (Study
design) was observed. We identified 45 articles consisting of
7 reviews and 38 original articles. These articles are presen-
ted in Table 1. In the intervention factor (I), we observed
Figure 1 - PRISMA records flow diagram.
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factors relating to diagnosis and factors relating to diagnostic
quality. We present the individual results of each factor.
Population
The incidence per 100,000 people differed, ranging from
9.5 in Nigeria (13) to 65 in the Fuji islands (14) and 92.2 in
French Polynesia (14). Regional variations were also obser-
ved, but the incidence was generally lower in DCs than in
developed countries (13, 14). Noteworthy regional reviews
are available for Arab countries (13, 15, 16), Asia (14, 17) and
Latin America (18).
Intervention/Diagnosis
Diagnostic strategy methodology/guidelines. In many
centers, breast self-examination (BSE) (19) and clinical breast
examination (CBE) are keys to diagnosis when mammo-
graphic diagnosis is not feasible (19, 20), but many women are
unaware of BSE and CBE (21). Furthermore, difficulties in
promoting education related to BSE have been cited (15), with
approximately 3% (22) to 24% of women administering a BSE
(21, 23) and 12.5% undergoing a CBE (15).
In countries lacking government recommendations regard-
ing mammography, the recommended starting age for routine
mammography varies widely, with starting ages of 25, 40,
or 50 years of age and upper limits of 64, 70, or 75 years
of age; both annual or biennial repetition are suggested (16,
18, 24-27).
Diagnostic infrastructure. A total of 5% of all world-
wide expenditure on breast cancer screening takes place in
DCs. This limitation in resources and the many competing
priorities mean that conducting mammography and provid-
ing effective treatment are difficult (28) and that most tumors
are consequently diagnosed at the advanced stages. Because
breast cancer is often a fatal disease in some countries (29),
screening and treatment are not considered cost-effective
(30). In addition, many countries lack a national program
(31-33) because national protocols regarding the appropriate
age range for mammography are not available (34). These
conditions lead to a lack of information about the importance
of mammography. Similarly, BSE and CBE can be used as
diagnostic and screening methods (35), but this strategy may
not be employed at the public health level. In Nigeria, 75.6%
of studied women had never performed a BSE, and only
58.2% had heard of BSEs (23). In Bangladesh, 41% of women
did not know what breast cancer is, 71% did not know what
screening is, and 96% did not know what a BSE is (36).
Some studies cite referral services that attenuate these prob-
lems and the use of breast ultrasound as an alternative method
for the diagnosis of palpable lesions (37). One study describes
four mammogram machines serving 7 million women (37),
and another states that only working women had access to
mammography (38). In fact, regions lacking public mammo-
graphy service have also been described (39). Therefore, diag-
nostic mammography rates are approximately 0.5% (33, 40).
Other reports describe slightly better situations, including
diagnostic mammography, population campaigns, and
opportunistic mammography. A study from Jordan reports
14 mammography centers, with 7% of the population having
mammograms and 17.9% having undergone screening (26).
In Mexico, 22% (24) of the population receives regular mam-
mograms. Positive educational interventions (41), isolated
regional experiences of the first round of mammographic screen-
ing (27, 42), and structured locations where only a minority of
patients are diagnosed late (43, 44) have been reported.
Percentage of women undergoing mammography. A
study conducted in Jamaica reported that 11.4% of women
had undergone a mammography at least 5 years ago (45).
In areas where mammography is opportunistically avai-
lable, 42.1% of women aged 40-69 years had never had a
mammogram (42), and these women are usually less educa-
ted and of a lower socioeconomic class (46).
Intervention/quality
Presentation of symptoms at diagnosis. In the absence
of screening strategies, clinical examination leads to diag-
nosis, and palpable tumors have been reported to represent
90 to 100% of all cases at diagnosis (33, 36, 44, 47). This pro-
portion decreases to 26% after opportunistic mammographic
screening (48).
The size of invasive tumors can also be used to evaluate
disease, and the average sizes in Singapore and Malaysia
are 2.2 cm and 3.0 cm, respectively (49). A review evaluating
tumor characteristics in Asia and Africa reveals tumors aver-
aging 3.3 cm in Tunisia, and 4.8 cm in Sudan and Nigeria.
In Pakistan, 80% of tumors are larger than 2 cm (50, 51).
Table 1 - Indirect indicators related to breast cancer diagnosis in DCs.
PICOT Factor Indicator
Population Breast cancer Epidemiological Incidence of breast cancer
Intervention Methodology or Diagnosis Diagnostic strategy methodology
diagnostic condition National Guidelines; Screening age range
Mammography infrastructure; % of population coverage
% of mammographies performed
Structuring of network with screening rounds
Quality Form of presentation of symptoms at diagnosis
Time to diagnosis
% of early-stage cases (CS 0, CS 0+1, localized/regional disease)
Comparator Control Trend curves/temporal data
Vulnerable subpopulations
Comparison among countries
Outcome Final outcome Survival Mortality/incidence ratio
Survival according to staging
CS = clinical stage.
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Time between the finding of a breast abnormality or
examination and diagnosis. Because of both technology-
based inefficiency and problems with access, few patients
undergo treatment in well-equipped centers that feature
protocols. Limited technology, economic reasons, and nutri-
tional problems lead to maintenance of the disease’s pre-
valence (20). Furthermore, this equipment may be available
but in insufficient numbers to serve the entire population
quickly. Therefore, a long time can elapse between a clinical
complaint and the start of treatment. In better structured
areas, limited equipment and diagnostic flow in the public
network leads to delays in diagnosis, which reportedly range
from 1 to 3 (52), 8 (53) and 10 months (33). These delays
are inversely proportional to the degree of organization of
the healthcare system (54). Generally, the delay is less than
1 month in developed countries and more than 2.5 months in
DCs (53).
Percentage of cases diagnosed at an early stage. In
general, the rate of patients diagnosed with carcinoma in situ
is low, ranging from 1% in India (17) and Pakistan (55) to
7.4% in Iran (56). Considering early stage as clinical stage (CS)
0 and I, the rate of individuals diagnosed with early-stage
tumors varies and is 5% in India (17), 10% in Pakistan (55),
and 13.9% in Iran (56). In Brazil, the introduction of a
regional screening program resulted in an increase in tumors
diagnosed during the early stage from 14.5% to 43.2% (42).
The infrastructure of Hong Kong differs and resulted in
detection rates of 13% for CS 0 and 47% for early-stage
disease (17). A study conducted in Malaysia compared
women selected with mammographic screening and diag-
nostic mammography and found respective CS 0 diagnosis
rates of 23.0% and 2.6% and respective early-stage cancer
diagnosis rates of 53.8% and 27.0% (48).
The localized/regional/metastatic staging methodology
is not used as frequently in publications in DCs, but we
observed differences in diagnosis rates between DCs and
developed countries (53, 57). Localized disease represents
25.2% of the tumors in Egypt, 27.8% in Saudi Arabia, 52.0%
in Germany and 62.3% in the US (53).
The TNM staging system is more often used in articles
related to DCs. When only invasive disease is evaluated,
stage I tumor staging rates were below 5% in India, the Phil-
ippines, and Nigeria, but the rates exceeded 30% in South
Korea and Taiwan (50, 51, 53). Based on three reviews (50, 51,
53), we compared the percentage of clinical stage I patients
and data from the Human Development Index (13, 58); we
chose the year 2008 as a reference because that was the
publication year of the articles reviewed. Only one publica-
tion was selected by country, and we chose only countries
with an estimated HDI. Data were entered and plotted using
IBM SPSS Statistics 20 for Macs (Armonk, New York, NY).
We observed a linear relationship (R2= 0,526) related to HDI
and clinical stage, as a high HDI was associated with a
higher rate of clinical stage I disease, and a lower HDI was
associated with lower rate (Figure 2).
Comparisons
Trend curves/temporal data. Studies demonstrating
temporal changes indirectly show changes in the healthcare
system. For example, a study in Egypt showed that the loca-
lized and metastatic disease rates were 14.8% and 14.0%
in 1999, respectively, whereas they were 20.8% and 11.9%,
respectively, in 2008. This change may be attributed to
improvements in the local healthcare system (59). Similarly, a
study of a Lebanese hospital showed a small improvement in
the early diagnosis rate (CS 0 + I), which was 23.8% from
1990-1995 but changed to 25.8% from 2008-2013 (25). A study
conducted in Iran did not show temporal changes in the
early-stage diagnoses between 1994-1997 and 2006-2009,
which were 13% and 13.9%, respectively (56).
Figure 2 - Scatter plot comparing the Human Development Index and the percentage of clinical stage I cases selected by country. PA =
Porto Alegre; SA = Saudi Arabia; SP = Sa˜o Paulo.
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Subpopulations in the same country. A study conduc-
ted in Iran compared women of different socioeconomic
classes; the BSE, CBE and mammography rates were 4.1%,
5.6% and 4.8%, respectively, among the poorest women and
83.9%, 90.3% and 87.4%, respectively, among women of a
higher socioeconomic class (60). Similarly, black people in
South Africa had lower rates of localized staging (5%) at
diagnosis compared with whites (31%), a fact that reflects
socioeconomic differences relating to diagnostic access (57, 61).
Comparisons among countries. Because of limitations
of organized databases in DCs, studies on this subject are
also limited. In Brazil, comparing a hospital records series
with Surveillance, Epidemiology and End Results (SEER)
data, Brazilian patients were younger, demonstrated a longer
medical history, presented with larger tumors and were less
likely to have clinical stage I disease (10.2% x 50.1%), which
were all reflected by the lower overall survival rate of 19.6
percentage points and a cancer specific survival of 26.9 per-
centage points. This effect almost disappeared when compar-
ing overall survival by stage [Figure 3 (62)], which suggests
that the difference may have been due to the excessive num-
ber of patients diagnosed at the early stage in the US (46).
Outcome/Survival. Despite the lower incidence rates,
45% of worldwide breast cancer cases and 54% of deaths due
to breast cancer worldwide occur in DCs (63). The mortality/
incidence ratio reflects the structure of these countries better
than simple numeric mortality data, and this ratio exceeds
50% in many countries (14, 18, 64). Moreover, the per capita
income directly correlates with incidence and inversely correlates
with mortality (65), reflecting late diagnoses, poor healthcare
and high mortality (66) in DCs. In many countries, incidence
(14) and mortality tended to increase (1, 18, 67), whereas mor-
tality tended to decrease in high-income countries (67).
Moreover, the survival rate was 11% higher in Singapore
than in Malaysia. However, differences in tumor size at
diagnosis, clinical stage at diagnosis, and treatment were also
observed, all of which contributed to a higher survival rate of
Singaporean patients (49).
’ DISCUSSION
This study is a literature review that describes potential
indicators related to the diagnosis of breast cancer in develop-
ing countries. Based on this study type, we opted to use the
methodology of systematic reviews, using PRISMA and
PICOTS, to evaluate possible ways that the health systems
in DCs can be assessed. It was not possible to perform a meta-
analysis with odds ratios and forest plots because a meta-
analysis requires case-control or randomized studies, which
are not often published in DCs. Because we found observa-
tional studies, prevalence studies and prevalence review
articles, we opted to perform an integrative systematic review.
The studies were summarized by topic according to the
PRISMA criteria for selection. We identified potential indica-
tors (Table 1) that can be used to compare differences and to
evaluate improvement in public health systems.
Figure 3 - Survival according to the SEER study (blue) and a Brazilian Oncologic Hospital (HCB, green). (a) Overall survival (OS); (b) cancer-
specific survival (SS); (c) overall survival selected by clinical stage (CS) at diagnosis. Unpublished Figure (ref 62) authorized by the Authors.
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BSEs and CBEs have long been considered to be important
methodologies to be implemented at the population level.
However, scientific evidence regarding the effectiveness of
CBEs or BSEs in reducing mortality from breast cancer is
currently lacking. Randomized studies carried out in China
(68) and Russia (69) have led to a loss in support for BSEs as
an early detection method because the breast cancer mor-
tality rates did not differ between women who performed
BSEs and those who did not. In this context, women are
encouraged to be alert to any changes in the breast, and CBEs
are part of this awareness and may lead the woman to a
diagnostic evaluation. According to the Brazilian Society for
Mastology, BSEs/CBEs in isolation are not encouraged but
are always associated with the use of mammography, espe-
cially in women over 40.
The sensitivity of breast self-examination (BSE) is low (20
to 30%), and it is not associated with a decrease in mortality.
Mammography has a sensitivity of 63 to 95% (37), and it
is the only exam that has been demonstrated to be related
to a decrease in mortality. Its sensitivity increases with the
presence of palpable lumps and decreases in dense breasts.
Approximately 10%-30% of breast cancers are not detected
by mammography because of many possible factors such as
dense parenchyma, obscure lesions, poor positioning, per-
ception error, incorrect interpretations, subtype tumors, slow
growing tumors, the presence of interval carcinomas and
smaller-sized tumors (70). Based on these factors, the woman
must perform a regular evaluation by BSE and/or undergo
a clinical breast evaluation by a healthcare professional. Together,
these exams must be considered in the diagnostic evaluation in
addition to a breast ultrasound in symptomatic women (71).
Breast cancer screening by mammography is the best
secondary prevention methodology for the population; it
serves as a disease intervention measure and promotes early
detection in the asymptomatic phase. Specifically, screening
substantially reduces the morbidity and mortality due to late
diagnosis. The HIP study (Health Insurance Plan) was the
first to demonstrate a reduction in breast cancer mortality
(30%) as a result of mammographic screening. In the 2006
and 2009 Cochrane reviews, the reduction was approxi-
mately 15%. In the last review (2013), which only evaluated
randomized studies, they did not observe a reduction in
mortality, but a reduction on the order of 25% was found
when observational studies were included; and when group-
ing all studies together, this reduction was 19% (72). The
greater likelihood of reducing breast cancer mortality in
several developed countries can be attributed to screening
programs and the evolution of adjunct therapy (73), (74).
More recent studies have questioned these figures, arguing
that this reduction is on the order of 8%, but these studies
were conducted in developed countries and many metho-
dological problems were questioned (75).
Screening primarily reduces mortality in women between
50 and 69-74 years of age, with less dramatic results in
women who are 40-49 years of age. Thus, mammography
should be performed on a large scale at the population level
for this age group to reduce breast cancer mortality. The
Brazilian Society of Mastology suggests that the starting
age should be 40 years (76), which was also suggested by
the American Cancer Society until 2015 (77). In 2016, this
suggestion was changed to age 45 (78). EUSOMA (12), the
US Preventive Services Task Force (79) and the Brazilian
Ministry of Health (42) suggest that organized population
screening commence at age 50.
Currently, many studies arguing against and in favor of
mammographic screening are available. Decreases in the size
of diagnosed lesions, decreases in breast cancer mortality,
longer lifespans, an acceptable overdiagnosis level (1-10%),
and the frequency of carcinoma in situ all support the use of
mammographic screening (12, 75, 80). Conversely, partial
evaluations of systematic reviews (80), discussions about the
actual decline in advanced stage tumors in the US (81), and
the rate of overdiagnosis (31%) (81) do not support the use of
mammographic screening. Moreover, although some studies
show that lives are indeed saved by mammographic screen-
ing, the number of survivors is low (82, 83). In general, stu-
dies of doctors who see patients support the use of screening
(75, 77), whereas studies performed by epidemiologists argue
against this type of screening (81), and suggest that women
should be well informed regarding mammographic screening
and aware of the pros and cons (82, 83). This fact is especially
relevant in developed countries, where high income and educa-
tion levels characterize much of the population.
In countries with extremely limited public health resources,
infectious diseases are the main public health problem. The
extent to which these diseases are controlled to increase life
expectancy changes disease profiles. The age distribution of
the population affects the incidence of cancer, with a decrease
in age at diagnosis being observed in some countries (37). In
DCs, most of the population earns a low income. Therefore,
healthcare usually depends on government actions and public
health infrastructure. Healthcare provision is related to the
availability of resources, and many diseases compete for these
resources. Public health practices are linked to national guide-
lines and available methodologies, which are associated with
public education processes and the availability of public net-
work demand absorbency. Therefore, not only tumor-related
or epidemiological criteria but also account resource avail-
ability are important when evaluating the age range for
screening strategies because data in DCs are generally limited
and rely on studies conducted in developed countries. Thus,
strategies are lacking, and BSEs are used as a screening
strategy, whereas ultrasound is used as a diagnostic strategy.
In DCs, mammograms are not performed primarily because
of barriers in the healthcare system, which are affected by the
following: the accessibility of health services, unsatisfactory
medical adherence due to public healthcare system limitations,
the cost of tests, and difficulty in implementing follow-up
tests (5, 84). The evaluation of factors relating to the health-
care system and non-adherence to mammogram screening
guidelines is complex because such evaluations lack a specific
indicator. The cultural context is interwoven with the infrastruc-
ture, the limitation of trained personnel, and the effective
stratification of examinations up to the point of diagnosis,
which should be quick, comprehensive, and effective. Never-
theless, this effect can be assessed by evaluating mammo-
graphy available to the public, population coverage, and the
percentage of mammography exams performed. In this con-
text, access to mammography refers to the presence of this
technology, the ease of the general population’s access to it, the
quality of the tests performed, and the possibility of perfor-
ming additional tests focused on biopsy and differential
diagnosis. Logistical and technological limitations delay tests
prior to diagnosis, result in low population coverage, and gene-
rally limit access to regular mammograms. DCs report difficul-
ties with respect to mammography screening in women, while
developed countries discuss the practice of mammography for
specific ages, as 57.2% of the women aged 50 to 74 in the
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US (85) undergo regular mammography. In addition, the
qualities of breast cancer screening methods and accreditation
programs are reported in developed countries (12, 86, 87). This
fact reflects the clinical stage at diagnosis, as early clinical stage
disease (EC 0 and I) represents 5% of all tumors in India (17)
and 50.9% in Europe (86). In DCs, tumors are usually palpable,
large, and not at an early clinical stage at the time of diagnosis
(Figure 2). Conversely, tumors diagnosed only by mammogra-
phy are infrequent, and the incidence of carcinoma in situ is
low. For example, carcinoma in situ varies and was 0.1% in
African registries, 1% in India, 11.4% in Europe, 16% in North
America and approximately 4.5% in other regions of the world
(9, 17, 86).
Although tumors smaller than 2 cm can be detected by
clinical examination, they must be superficial, and the great
majority of these tumors that are detected by mammography
are smaller than 2 cm (88). Technology is associated with a
local infrastructure and is based on mammograms, ultra-
sound, biopsy (open or core biopsy) and pathology. This
reflects the lower percentage of early breast cancers detected
in DCs. The HDI shows the association of PIB per capita and
the life expectancy, which may indirectly reflect the health
system. People have a socioeconomic dependence on public
health systems, and therefore, the public health system is
not a choice but may be the only option for many women. To
evaluate the clinical stage at diagnosis, the TNM staging
system is a standard and acceptable approach. We observed
different frequencies of stages based on clinical stage 0 to IV
(five categories) or clinical stage I to IV (four categories). The
evaluation of the percentage of cases at clinical stage 0 would
be based primarily on mammography-detected tumors, but
these data were not reported in all the included studies. If we
use the four categories listed above, we must pay attention
to clinical stage I. Tumors larger than 2 cm are frequently
palpable and clinically detectable. Based on this observation,
we generated Figure 2 and chose data from clinical stage I to
IV, as data related to clinical stage 0 were insufficient. We
observed a linear relationship of the HDI and clinical stage,
as a high HDI was associated with a higher rate of clinical
stage I, while a lower HDI was associated with lower clinical
stage I (Figure 2).
In terms of survival, patients with early-stage disease
exhibit excellent survival rates, whereas patients with meta-
stasis at the time of diagnosis have limited survival. Dif-
ferences in survival are primarily due to differences in
clinical stage at the time of diagnosis and the ability to
provide adjunct therapy at the population level, which is
reflected in the 5-year survival rates in different countries
(89). The CONCORD study evaluated population-based
cancer registries from 2005-2009 and estimated the 5-year
survival rate after observing lower survival rates in South
Africa (53%), Mongolia (57%), India (60%) and higher
survival rates in North America and Oceania (84-89%).
Its study showed that differences in the 5-year cancer
specific-survival were dependent on the country (9). After
a comparison of the SEER database with an institutional
Brazilian database adjusted by the same characteristics, a
similar 10-year global survival rate was observed according
to clinical stage, which reminds us to consider the influence
of the percentage of early clinical stage cases on the overall
survival, and the importance of long-term follow-up. In this
publication, the cancer-specific survival was not discussed,
and differences were observed in patients with clinical stage I
(3.6 at 5-years and 13.0% at 10-years; p=0.001) and clinical
stage II (4.7 pp at 5-years and 6.6 pp at 10-years; p=0.001)
disease. However, these differences were associated with the
quality of mortality data, the loss of follow-up information,
as well as differences in treatment protocols and molecular
subtypes, which renders it difficult to make comparisons
among countries (62).
If we consider that mammographic screening and early
diagnosis are not related to an increase in the survival, as
shown in some randomized studies, we must not forget that
these studies were performed in developed countries, where
favorable conditions are present for diagnosis and treatment.
In reality, the opposite conditions are present in DCs, a fact
that reflects the lower rate of early diagnosis and poor sur-
vival. It is therefore important to have a progressive structur-
ing of public health systems. To evaluate this condition, we
found possible indicators that can be reported and that can be
used in future studies performed in DCs (Table 1).
The identification of subpopulations or analysis based on
socioeconomic conditions helps to understand the context
of a population that is more dependent on the public health-
care system. Similarly, the observation of temporal data
allows us to evaluate progress relating to the structuring of
the public healthcare system. Limitations in diagnosis and
treatment lead to a high mortality/incidence ratio (74); speci-
fically, diagnosis is delayed, and many treatments are not
performed based on protocols (20).
When using the PICOTS methodology for diagnostic tests
(11), the Timing (T) and Setting (S) are observed, but studies
of these factors were not available. Therefore, we present
general aspects (PICO; Table 1). Some review articles on the
subject were included in the overall review, but they were
not selected in the 45 articles that determined the indicators
because they do not show potential indicators.
Two aspects should be emphasized in this study. In the
initial evaluation, the search was conducted using keywords
that are associated with case-control studies. This search
revealed 4 publications, but none of these publications
included possible indicators, which led us to review gene-
ral articles to identify possible indicators. Furthermore, the
separation between DCs and underdeveloped countries
presented another problem. The literature evaluated lacks a
clear separation between the two, despite the possibility of
using World Bank classifications (90). Therefore, underdevel-
oped countries could not be excluded from the evaluation.
Limitations of the present study include the following:
only 1 database was used; the evaluation of articles was
not based on the level of evidence but rather on available
data, which we attempted to systematically evaluate; and
comparisons of all indicators in developed countries were
not reported. The objective was to identify potential indi-
cators identified by a systematic methodology. Consequently,
indirect indicators that can be used in DCs were identified,
which elucidated the conditions relating to breast cancer
diagnosis in DCs. The systematic identification and descrip-
tion of these indicators will facilitate comparisons among
countries, the evaluation of public services, and the evalua-
tion of outcomes of the progressive structuring of healthcare
systems.
Currently, the validity of mammographic screening and
mammography is under discussion, but such discussions are
carried out in countries with structured healthcare systems
that allow for diagnosis and treatment, irrespective of who
absorbs the costs of this process. A better understanding of the
alternate reality, that is, comparisons between limited public
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healthcare systems in terms of technology or access to mam-
mography, will enable us to better understand the benefits of
this diagnostic modality and mammographic screening.
Mammographic screening is proved to be beneficial when
it is performed in an organized and regular manner in the
form of a national public health policy or when the per capita
income of the population allows it to absorb most of the
costs. Therefore, organized screening is difficult in DCs, but
the progressive structuring of healthcare services can signif-
icantly attenuate this problem. The socioeconomic depen-
dence and late diagnosis reflect the higher morbidity and
mortality rates of breast cancer in DCs. The impact of mam-
mographic screening may be more beneficial in DCs than
what is observed in developed countries. This structuring
can be evaluated using indicators relating to diagnostic qua-
lity or methodology, and this study identified these indi-
cators. These indicators will facilitate the evaluation of the
improvement in health systems related to breast cancer and
will allow comparisons among countries. This will provide
us with a better understanding of the real impact of mam-
mographic screening in DCs.
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